Thinking about buying stock in Adaptimmune Therapeutics, Ziopharm Oncology, Uniqure NV, GlycoMimetics, or AbCellera Biologics?
NEW YORK, Sept. 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADAP, ZIOP, QURE, GLYC, and ABCL.
To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.
- ADAP: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=ADAP&prnumber=090720211
- ZIOP: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=ZIOP&prnumber=090720211
- QURE: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=QURE&prnumber=090720211
- GLYC: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=GLYC&prnumber=090720211
- ABCL: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=ABCL&prnumber=090720211
(Note: You may have to copy this link into your browser then press the [ENTER] key.)
InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
View original content to download multimedia:https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-adaptimmune-therapeutics-ziopharm-oncology-uniqure-nv-glycomimetics-or-abcellera-biologics-301370225.html
Adaptimmune's Cell Therapy Shows Antitumor Activity in Early Stage Study; Shares Down Midday
MT Newswires 09/13 12:47 ET
European ADRs Rise 1% Monday as Energy Giants Gain, Pharma Retreats
MT Newswires 09/13 11:08 ET
AbCellera Biologics Buys TetraGenetics
MT Newswires 09/13 11:00 ET
--SVB Leerink Adjusts Adaptimmune Therapeutics PT to $7 From $6, Maintains Market Perform Rating
MT Newswires 09/13 10:55 ET
AbCellera acquires TetraGenetics for enhancing capabilities to generate antibodies
SA Breaking News 09/13 09:50 ET
Adaptimmune Shares Encouraging Data From Solid Tumor Trial
Yahoo 09/13 09:50 ET
AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets
Yahoo 09/13 09:00 ET
Thinking about buying stock in Leap Therapeutics, Aterian, Hepion Pharmaceuticals, Adaptimmune Therapeutics, or Endo International?
PR Newswire 09/13 08:30 ET
Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial
Globe Newswire 09/13 07:00 ET
AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference
Yahoo 09/10 16:17 ET